Obstetric Indications for Progestin Therapy - 21/02/23
Doi : 10.1016/j.ogc.2022.10.004
Rupsa C. Boelig, MD, MS a, b, ⁎ 
a Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, 833 Chestnut Street, Level 1, Philadelphia, PA 19107, USA
b Department of Clinical Pharmacology and Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
∗Corresponding author.
Résumé |
Specifically, meta-analyses of randomized trials demonstrate that vaginal progesterone reduces the risk of preterm birth in selected high-risk singleton pregnancies. 17-OHPC may also reduce the risk of recurrent preterm birth in singletons. Finally, one trial suggests that vaginal progesterone may also be beneficial in improving live birth rates in singletons with prior miscarriages and early pregnancy bleeding.
Le texte complet de cet article est disponible en PDF.Keywords : Progestin, Progesterone, 17-OHPC, 17-hydroxyprogesterone caproate, Preterm birth
Plan
© 2022
Elsevier Inc. Tous droits réservés.
Vol 50 - N° 1
P. 101-107 - mars 2023 Retour au numéro
Article précédent
- Magnesium Sulfate Use in Pregnancy for Preeclampsia Prophylaxis and Fetal Neuroprotection : Regimens in High-Income and Low/Middle-Income Countries
- Kathleen F. Brookfield, Osinakachukwu Mbata
- Antenatal Steroids and Tocolytics in Pregnancy
- Kelsey Pinson, Cynthia Gyamfi-Bannerman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?